Leerink Partnrs Issues Negative Forecast for AbbVie Earnings
Investment analysts at Leerink Partnrs dropped their FY2024 EPS estimates for AbbVie in a research note issued to investors ...
Aspira Women's Health Announces the Appointment of Mike Buhle as SVP of Commercial Operations
AUSTIN, TX / ACCESSWIRE / January 10, 2025 / Aspira Women's Health Inc. ('Aspira' or the 'Company') (Nasdaq:AWH), a bio-analytical based women's health company focused on the development of ...
Apellis Announces Keli Walbert to Join the Board of Directors
WALTHAM, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: APLS) today announced that Keli Walbert will join the Apellis Board of Directors, effective immediately. Ms. Walbert brings more than two ...
Royalty Pharma Announces Transformative Step in Company’s Evolution With Acquisition of its External Manager and $3 Billion Share Repurchase Program
Royalty Pharma plc to become an integrated company by acquiring its external manager, RP Management, LLCSignificant annual cash savings of ...
Le Lézard3h
Serna Bio Announces Scientific Advisory Board
Serna Bio, an AI drug discovery company pioneering RNA-targeting small molecules, today announced the members of its Scientific Advisory Board (SAB). Established in 2021, Serna Bio is a preclinical ...
The Pharmaceutical R&D Outsourcing Market on Track for $150 Billion Milestone, North America Takes the Spotlight – Arizton
Role of Real-World Evidence (RWE) in Driving Pharmaceutical R&D Outsourcing Market Growth ...
Abbvie to record $3.5 bln charge related to schizophrenia drug
Abbvie said on Friday it would record a charge of about $3.5 billion related to its experimental schizophrenia drug, ...
AbbVie Takes $3.5B Impairment Charge for Failed Schizophrenia Drug
AbbVie said it would take a $3.5 billion dollar impairment charge related to the failure of a drug it acquired in its ...
FierceBiotech1h
AbbVie takes $3.5B hit after emraclidine's phase 2 flop in schizophrenia
The failure of Cerevel's emraclidine in schizophrenia will cost AbbVie an impairment charge of about $3.5 billion, the pharma ...
AbbVie to Post $3.5 Billion Impairment Charge on Failed Cerevel Drug
AbbVie said the impairment charge is related to last year’s $8.7 billion bet on Cerevel following the failure of the deal’s ...
Abbvie to record $3.5 billion charge related to schizophrenia drug
Abbvie said on Friday it would record a charge of about $3.5 billion related to its experimental schizophrenia drug, ...
AbbVie to record $3.5B impairment charge for Cerevel drug
AbbVie (NYSE:ABBV) said it expects to record an impairment charge of approximately $3.5B related to the drug emraclidine, ...